Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Level-Up: upadacitinib versus dupilumab in moderate to severe atopic dermatitis
NL-OMON53823Phase 4Completed
- Sponsor
- Site Management & Monitoring
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of upadacitinib and dupilumab, sponsored by Site Management & Monitoring. Started Aug 2023; status: completed.
02
Drugs
upadacitinibdupilumab
Beyond the preview
Go deeper on NL-OMON53823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53823.